Turmeric and symptoms after menopause
Hot-flash frequency and overall symptom scores in a study of a curcuminoid blend.
Key points
- In postmenopausal women, the studied blend reduced hot-flash frequency by about seven per week more than placebo over 12 weeks. For this blend there is a preliminary signal of less frequent hot flashes. [1] See the evidence 1
- In the same study no advantage of the blend was found for overall quality of life or overall symptom score. The hot-flash result should not be transferred to all menopausal symptoms. [1] See the evidence 1 2
Practical guide
Check the conclusions and whether they apply to your situation.
Hot-flash frequency and overall quality-of-life and symptom scores were measured separately.
Key points
Why these conclusions
Pilot study
Postmenopausal women aged 41–65 took standardized turmeric extract with a curcuminoid blend: four capsules, 1000 mg curcuminoids total daily, or placebo for 12 weeks. Hot-flash frequency decreased about seven per week more with the studied blend. [1]
At week 12, no advantage was found for overall MENQOL quality of life or overall MRS II symptom score. [1]
TGA warns of rare, sometimes severe liver injury from turmeric or curcumin supplements. Risk may be higher with enhanced-absorption supplements or high doses. Stop and seek medical help for jaundice, dark urine or unusual weakness; avoid such supplements with current or past liver disease. [2]
In postmenopausal women, the studied standardized blend reduced hot-flash frequency by about seven per week more than placebo over 12 weeks.
| Parameter | Data |
|---|---|
| Result | In postmenopausal women, the studied standardized blend reduced hot-flash frequency by about seven per week more than placebo over 12 weeks. Difference in changes −7.35 hot flashes/week (95% CI −10.29 to −4.41), p<0.001. |
| Participants | 40 postmenopausal women aged 41–65, double-blind pilot RCT |
| Form | Oral standardized turmeric extract with curcuminoid blend |
| Dose | 4 capsules, each 294.12 mg extract with 250 mg curcuminoids; 1000 mg curcuminoids/day |
| Dose basis | 4 capsules, each 294.12 mg extract with 250 mg curcuminoids; 1000 mg curcuminoids/day |
| Comparator | placebo |
| Duration | 12 weeks |
| Confidence | 2/4: Precision: Confidence interval allows a change of around one hot flash per day or less. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Measurement directly addresses the stated narrow PICO. Possible publication bias: No specific data for a separate downgrade. Study methods: Retrospective registration, small pilot. |
| Evidence base | 1 randomized trial |
| Sources | [1] |
At week 12 no advantage of the studied blend over placebo was found for overall MENQOL quality of life.
| Parameter | Data |
|---|---|
| Result | At week 12 no advantage of the studied blend over placebo was found for overall MENQOL quality of life. No significant between-group difference at week 12. |
| Participants | The same 40 postmenopausal women aged 41–65. |
| Form | Standardized turmeric extract, 4 capsules |
| Dose | 1000 mg curcuminoids/day |
| Dose basis | 1000 mg curcuminoids/day |
| Comparator | placebo |
| Duration | 12 weeks |
| Confidence | 2/4: Precision: Small sample, exact contrast confidence interval not confirmed. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Measurement directly addresses the stated narrow PICO. Possible publication bias: No specific data for a separate downgrade. Study methods: Pilot with retrospective registration and several secondary outcomes. |
| Evidence base | 1 randomized trial |
| Sources | [1] |
At week 12 no advantage of the studied blend over placebo was found for overall MRS II symptom score.
| Parameter | Data |
|---|---|
| Result | At week 12 no advantage of the studied blend over placebo was found for overall MRS II symptom score. No significant between-group difference at week 12. |
| Participants | The same 40 postmenopausal women aged 41–65. |
| Form | Standardized turmeric extract, 4 capsules |
| Dose | 1000 mg curcuminoids/day |
| Dose basis | 1000 mg curcuminoids/day |
| Comparator | placebo |
| Duration | 12 weeks |
| Confidence | 2/4: Precision: Small sample, exact contrast confidence interval not confirmed. Consistency: No grounds for a separate downgrade. Applicability to the specified group: Measurement directly addresses the stated narrow PICO. Possible publication bias: No specific data for a separate downgrade. Study methods: Pilot with retrospective registration and several secondary outcomes. |
| Evidence base | 1 randomized trial |
| Sources | [1] |
TGA warns of rare, sometimes severe liver injury from turmeric or curcumin supplements. Risk may be higher with enhanced-absorption supplements or high doses. Stop and seek medical help for jaundice, dark urine or unusual weakness; avoid such supplements with current or past liver disease.
TGA warns of rare, sometimes severe liver injury from turmeric or curcumin supplements. Risk may be higher with enhanced-absorption supplements or high doses. Stop and seek medical help for jaundice, dark urine or unusual weakness; avoid such supplements with current or past liver disease. [2]
More details
What the result means
The preliminary signal applies to hot-flash frequency in a trial of a specific blend; overall quality-of-life and symptom scores showed no advantage. [1]
Sources
- Curcuminoid supplementation for vasomotor symptoms in postmenopausal women: a pilot, randomized, double-blind, placebo-controlled proof-of-concept trial. https://link.springer.com/article/10.1186/s12906-026-05358-7
- TGA Medicines containing turmeric or curcumin - risk of liver injury. https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/medicines-containing-turmeric-or-curcumin-risk-liver-injury
Methodology: Subpages evidence-led supplement pipeline v1